RU2020111236A3 - - Google Patents

Download PDF

Info

Publication number
RU2020111236A3
RU2020111236A3 RU2020111236A RU2020111236A RU2020111236A3 RU 2020111236 A3 RU2020111236 A3 RU 2020111236A3 RU 2020111236 A RU2020111236 A RU 2020111236A RU 2020111236 A RU2020111236 A RU 2020111236A RU 2020111236 A3 RU2020111236 A3 RU 2020111236A3
Authority
RU
Russia
Application number
RU2020111236A
Other languages
Russian (ru)
Other versions
RU2020111236A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2020111236A publication Critical patent/RU2020111236A/ru
Publication of RU2020111236A3 publication Critical patent/RU2020111236A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2020111236A 2008-07-17 2020-03-18 Терапевтическое дозирование нейрегулина или его подпоследовательности для лечения или профилактики сердечной недостаточности RU2020111236A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13517108P 2008-07-17 2008-07-17
US61/135.171 2008-07-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2019125376A Division RU2719199C1 (ru) 2008-07-17 2019-08-12 Терапевтическое дозирование нейрегулина или его подпоследовательности для лечения или профилактики сердечной недостаточности

Publications (2)

Publication Number Publication Date
RU2020111236A RU2020111236A (ru) 2021-09-21
RU2020111236A3 true RU2020111236A3 (enExample) 2021-09-21

Family

ID=42005671

Family Applications (4)

Application Number Title Priority Date Filing Date
RU2011105821/10A RU2536938C2 (ru) 2008-07-17 2009-07-17 Применение пептида ggf2 в лечении или профилактике сердечной недостаточности у млекопитающего
RU2014141514A RU2698090C2 (ru) 2008-07-17 2014-10-14 Терапевтическое дозирование нейрегулина или его подпоследовательности для лечения или профилактики сердечной недостаточности
RU2019125376A RU2719199C1 (ru) 2008-07-17 2019-08-12 Терапевтическое дозирование нейрегулина или его подпоследовательности для лечения или профилактики сердечной недостаточности
RU2020111236A RU2020111236A (ru) 2008-07-17 2020-03-18 Терапевтическое дозирование нейрегулина или его подпоследовательности для лечения или профилактики сердечной недостаточности

Family Applications Before (3)

Application Number Title Priority Date Filing Date
RU2011105821/10A RU2536938C2 (ru) 2008-07-17 2009-07-17 Применение пептида ggf2 в лечении или профилактике сердечной недостаточности у млекопитающего
RU2014141514A RU2698090C2 (ru) 2008-07-17 2014-10-14 Терапевтическое дозирование нейрегулина или его подпоследовательности для лечения или профилактики сердечной недостаточности
RU2019125376A RU2719199C1 (ru) 2008-07-17 2019-08-12 Терапевтическое дозирование нейрегулина или его подпоследовательности для лечения или профилактики сердечной недостаточности

Country Status (13)

Country Link
US (5) US20110166068A1 (enExample)
EP (3) EP2320933B1 (enExample)
JP (5) JP5797112B2 (enExample)
CN (3) CN107019794B (enExample)
AU (3) AU2009292216B2 (enExample)
BR (1) BRPI0916442A2 (enExample)
CA (1) CA2731113A1 (enExample)
DK (2) DK3338791T3 (enExample)
ES (2) ES2664394T3 (enExample)
MX (2) MX384378B (enExample)
PL (2) PL3338791T3 (enExample)
RU (4) RU2536938C2 (enExample)
WO (1) WO2010030317A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110166068A1 (en) 2008-07-17 2011-07-07 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Subsequence Thereof for Treatment or Pro-phylaxis of Heart Failure
EP2328606B1 (en) 2008-08-15 2016-10-05 Acorda Therapeutics, Inc. Compositions and methods for treatment during non-acute periods following cns neurological injury
EP2808339B1 (en) * 2008-11-28 2017-02-15 Zensun (Shanghai) Science & Technology, Co., Ltd. Neuregulin peptides and their use
BR112012008821A2 (pt) 2009-10-14 2020-09-15 Acorda Therapeutics, Inc. uso de neuregulina para tratar lesões nervosas periféricas.
WO2013053076A1 (en) * 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
CN104321072A (zh) * 2012-03-30 2015-01-28 阿寇达医疗有限公司 神经调节蛋白在治疗外周神经损伤中的应用
US20160129084A1 (en) * 2013-03-06 2016-05-12 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Fragment Thereof for Treatment or Prophylaxis of Heart Failure
EP2999499B1 (en) 2013-05-22 2019-07-17 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for treating heart failure
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
CN111407882A (zh) * 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
CA2999301A1 (en) 2015-09-25 2017-03-30 Douglas B. Sawyer Methods for treating cardiac injury
WO2017182500A1 (en) * 2016-04-19 2017-10-26 Leibniz-Institut Für Alternsforschung - Fritz-Lipmann-Institut E.V. (Fli) Neuregulin for the treatment and/or prevention of tumors of the nervous system
CN110835368A (zh) * 2018-08-15 2020-02-25 上海泽生科技开发股份有限公司 神经调节蛋白多肽片段及其用途
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
US20230057622A1 (en) * 2019-09-16 2023-02-23 Zensun (Shanghai) Science & Technology, Co., Ltd. Recombinant Human Neuregulin Derivatives and Use Thereof
WO2023070078A1 (en) * 2021-10-22 2023-04-27 The Research Institute At Nationwide Children's Hospital Neuregulin for protection against respiratory viral infection and post-viral disease

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US7115554B1 (en) * 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7037888B1 (en) 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
US6087323A (en) 1992-04-03 2000-07-11 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
US5811098A (en) * 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
US6136558A (en) * 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
US6051401A (en) 1998-07-28 2000-04-18 Bayer Corporation Methods and constructs for protein expression
DK1115417T3 (da) 1998-09-25 2006-07-31 Cubist Pharm Inc Anvendelse af daptomycin
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) * 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
CA2388918A1 (en) 1999-11-12 2001-05-17 Entremed, Inc. Methods for administration of therapeutic agents on an antiangiogenic schedule
ES2610353T3 (es) 2000-05-23 2017-04-27 Cenes Pharmaceuticals, Inc. Moléculas de ácido nucleico NRG-2, polipéptidos y métodos diagnósticos y terapéuticos
CU23157A1 (es) * 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
EP1569689A4 (en) 2002-01-18 2009-08-05 Novartis Vaccines & Diagnostic IL2 / ANTI-HER2-ANTIBODY COMBINATION THERAPY AGAINST CANCER, which is characterized by overexpression of the HER2-RECEPTOR PROTEIN
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
JP2008530186A (ja) * 2005-02-18 2008-08-07 オリオン コーポレーション 心不全治療法
BRPI0609427A2 (pt) 2005-03-23 2010-04-06 Pfizer Prod Inc composição farmacêutica para o tratamento de cáncer de próstata e uso de um agente de terapia hormonal e de um anticorpo, ou uma porção de ligação a antìgeno do mesmo
WO2007028085A2 (en) 2005-09-02 2007-03-08 Morehouse School Of Medicine Neuregulin for prevention and treatment of damage from acute assault on vascular and neuronal tissues
US20070213264A1 (en) * 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
JP5738516B2 (ja) * 2005-12-30 2015-06-24 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド 心機能改善のためのニューレグリンの徐放
US8410050B2 (en) 2008-02-29 2013-04-02 Acorda Therapeutics, Inc. Method for achieving desired glial growth factor 2 plasma levels
US20110166068A1 (en) * 2008-07-17 2011-07-07 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Subsequence Thereof for Treatment or Pro-phylaxis of Heart Failure
BR112012008821A2 (pt) 2009-10-14 2020-09-15 Acorda Therapeutics, Inc. uso de neuregulina para tratar lesões nervosas periféricas.
CA2845198A1 (en) 2010-08-13 2012-02-16 Georgetown University Ggf2 and methods of use
CN104321072A (zh) 2012-03-30 2015-01-28 阿寇达医疗有限公司 神经调节蛋白在治疗外周神经损伤中的应用

Also Published As

Publication number Publication date
US9956266B2 (en) 2018-05-01
AU2009292216A1 (en) 2010-03-18
AU2009292216B2 (en) 2015-03-05
EP2320933B1 (en) 2017-12-27
DK3338791T3 (da) 2019-12-16
PL2320933T3 (pl) 2018-07-31
RU2719199C1 (ru) 2020-04-17
RU2536938C2 (ru) 2014-12-27
CA2731113A1 (en) 2010-03-18
AU2015202877A1 (en) 2015-06-18
AU2017203528A1 (en) 2017-06-15
EP3632459A1 (en) 2020-04-08
CN107019794A (zh) 2017-08-08
PL3338791T3 (pl) 2020-04-30
JP2017200949A (ja) 2017-11-09
ES2763184T3 (es) 2020-05-27
US11235031B2 (en) 2022-02-01
RU2011105821A (ru) 2012-08-27
RU2020111236A (ru) 2021-09-21
CN104623633A (zh) 2015-05-20
US9198951B2 (en) 2015-12-01
BRPI0916442A2 (pt) 2018-06-19
US20200009228A1 (en) 2020-01-09
MX2011000696A (es) 2011-07-29
RU2014141514A (ru) 2016-05-10
JP5797112B2 (ja) 2015-10-21
EP3338791B1 (en) 2019-09-18
EP2320933A1 (en) 2011-05-18
US20160113999A1 (en) 2016-04-28
CN107019794B (zh) 2021-03-12
CN102159236A (zh) 2011-08-17
JP2019196370A (ja) 2019-11-14
DK2320933T3 (en) 2018-04-16
ES2664394T3 (es) 2018-04-19
EP2320933A4 (en) 2013-02-27
MX384378B (es) 2025-03-14
US20110166068A1 (en) 2011-07-07
JP2015129137A (ja) 2015-07-16
WO2010030317A2 (en) 2010-03-18
US20130324466A1 (en) 2013-12-05
RU2698090C2 (ru) 2019-08-22
JP2011528353A (ja) 2011-11-17
JP2022023208A (ja) 2022-02-07
AU2015202877B2 (en) 2017-03-09
EP3338791A1 (en) 2018-06-27
JP6189879B2 (ja) 2017-08-30
US20180280477A1 (en) 2018-10-04
HK1256637A1 (en) 2019-09-27

Similar Documents

Publication Publication Date Title
BR112016019572A2 (enExample)
BRPI0917573A2 (enExample)
BRPI0918697A2 (enExample)
BRPI0917525A2 (enExample)
BRPI0920750A2 (enExample)
BRPI0919470A2 (enExample)
BRPI0907698A2 (enExample)
BRPI0917618A8 (enExample)
BRPI0922455A2 (enExample)
BRPI0912727A2 (enExample)
BRPI0922669A2 (enExample)
BRPI0908285A2 (enExample)
BRPI0914750A2 (enExample)
BRPI0919811A2 (enExample)
BRPI0915616A2 (enExample)
BRPI0908120A2 (enExample)
BRPI0904541A8 (enExample)
BRPI0912462A2 (enExample)
BRPI0922550A2 (enExample)
BRPI0916284A2 (enExample)
BRPI0913605A2 (enExample)
BRPI0911617A2 (enExample)
BRPI0909508A2 (enExample)
BRPI0914852A2 (enExample)
CH2352018H2 (enExample)